Cargando…

Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients With End-Stage Renal Disease Undergoing Hemodialysis

Background Patients on hemodialysis (HD) are most likely to contract hepatitis C (HCV) infection, which is associated with significant morbidity and disease progression. Direct-acting antivirals (DAAs) are safe and tolerable in chronic kidney disease (CKD) with a 90-100% cure rate, and limited data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shahid, Salman, Asghar, Shoaib, Mahmood, Tayyab, Fatima, Mishal, Rasheed, Ali, Asghar, Sohaib
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Gastroenterology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590019/ https://www.ncbi.nlm.nih.gov/pubmed/37868481 http://dx.doi.org/10.7759/cureus.45680

Ejemplares similares

Achieving the Sustained Virologic Response With a Short-Course Treatment of Sofosbuvir/Velpatasvir
por: Abi-Saleh, Simon P, et al.
Publicado: (2023)

Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir Regimen
por: Butt, Nazish, et al.
Publicado: (2019)

Efficacy and Safety of Sofosbuvir-Velpatasvir combination in Hepatitis C Virus-infected Pakistani Patients without Cirrhosis or with Compensated Cirrhosis: A Prospective, Open-label Interventional Trial
por: Butt, Nazish, et al.
Publicado: (2020)

Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir‐containing regimen: Results from a retreatment study
por: Ruane, Peter, et al.
Publicado: (2019)

Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
Publicado: (2019)

Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection
por: Shin, Hyun Phil
Publicado: (2023)

Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study
por: Heo, Jeong, et al.
Publicado: (2023)

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure
por: Mir, Fazia, et al.
Publicado: (2017)

Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C
por: Childs-Kean, Lindsey M, et al.
Publicado: (2019)

Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection
por: Anna, Linda Zignego, et al.
Publicado: (2018)

Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis
por: Ren, Xiao-Dan, et al.
Publicado: (2022)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
por: Mushtaq, Saima, et al.
Publicado: (2020)

Metabolic Syndrome in Type 2 Diabetes Mellitus Patients: Prevalence, Risk Factors, and Associated Microvascular Complications
por: Asghar, Shoaib, et al.
Publicado: (2023)

Eliminating hepatitis C in a rural Appalachian county: protocol for the Kentucky Viral Hepatitis Treatment Study (KeY Treat), a phase IV, single-arm, open-label trial of sofosbuvir/velpatasvir for the treatment of hepatitis C
por: Havens, Jennifer R, et al.
Publicado: (2021)

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
por: Janjua, Naveed Z., et al.
Publicado: (2019)

Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients – short report
por: Piekarska, Anna, et al.
Publicado: (2020)

Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India
por: Sood, Ajit, et al.
Publicado: (2019)

Perioperative Management and Surgical Outcomes of Colorectal Cancer Patients Undergoing Peritoneal Dialysis for End-Stage Kidney Disease
por: Kouno, Nobuji, et al.
Publicado: (2022)

Efficacy of 12-weeks velpatasvir plus sofosbuvir-based regimen in HCV-naive subjects with mild fibrosis: a meta-analysis
por: Mariantonietta, Pisaturo, et al.
Publicado: (2019)

Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection
por: Ahmed, Rowan, et al.
Publicado: (2021)

Microalbuminuria as the Tip of Iceberg in Type 2 Diabetes Mellitus: Prevalence, Risk Factors, and Associated Diabetic Complications
por: Asghar, Sohaib, et al.
Publicado: (2023)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany
por: Buggisch, Peter, et al.
Publicado: (2019)

Successful Treatment with Crushed Sofosbuvir/Velpatasvir of a Patient with Decompensated Cirrhosis C and Thrombocytopenia
por: Murayama, Aiko, et al.
Publicado: (2021)

Selective and sensitive spectrofluorimetric quantification of velpatasvir in presence of sofosbuvir. Application to their co-formulated tablet
por: El-Gamal, Rania M., et al.
Publicado: (2018)

Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India
por: Bloom, David E., et al.
Publicado: (2021)

Paraphenylenediamine (Hair Dye) Poisoning: A Prospective Study on the Clinical Outcome and Side Effects Profile
por: Asghar, Sohaib, et al.
Publicado: (2022)

Efficacy and Safety of Sofosbuvir and Ribavirin for Treating Chronic Hepatitis C, Genotype 3: Experience of a Tertiary Care Hospital at Karachi, Pakistan
por: Butt, Nazish, et al.
Publicado: (2019)

A Non-invasive 24 Hours Stabilization of Duodenal Ulcer Perforation by a Combination Regimen
por: Zil-E-Ali, Ahsan, et al.
Publicado: (2016)

Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation
por: Cardona‐Gonzalez, Maria G., et al.
Publicado: (2018)

Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19
por: Messina, Vincenzo, et al.
Publicado: (2022)

Efficacy and Safety of Sofosbuvir and Velpatasvir Combination for the Treatment of Chronic Hepatitis C in Patients With or Without Cirrhosis
por: Shah, Islam, et al.
Publicado: (2021)

Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?
por: Bourlière, Marc, et al.
Publicado: (2018)

Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
por: Flamm, Steven, et al.
Publicado: (2023)

The Novel Finding of Dynamic Change in eGFR Up to One Year after End of Treatment in HCV-Infected Patients Receiving Sofosbuvir and Velpatasvir
por: Wu, Cheng-Kun, et al.
Publicado: (2022)

Rare Mucinous Adenocarcinoma of the Appendix Undergoing Multiple Recurrent Surgical Interventions
por: Ilyas, Usman, et al.
Publicado: (2023)

The Potential Role of Model for End-Stage Liver Disease (MELD)-Sodium Score in Predicting the Severity of Acute Pancreatitis
por: Nayci, Ali Emre, et al.
Publicado: (2022)

Comparative Effectiveness of Laparoscopic Sleeve Gastrectomy in Morbidly Obese and Super Obese Patients
por: Khan, Ishfaq A, et al.
Publicado: (2021)

Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen
por: Agarwal, Sanjay Kumar, et al.
Publicado: (2017)

Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China
por: Zhang, Hedong, et al.
Publicado: (2022)

Effectiveness and Safety of Sofosbuvir-Velpatasvir in Patients with Cirrhosis Associated with Genotype 3 Hepatitis C Infection in Xinjiang, China
por: Abulitifu, Yilihamu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g2o6tunquo85chhq1fkjfcvasa